Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-positive Locally Advanced Breast Cancer Patients

NCT04126525 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT04126525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04126525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-positive Locally Advanced Breast Cancer Patients
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 18, 2019
Completion date
November 30, 2026
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female